72 related articles for article (PubMed ID: 30086464)
1. Dual functional roles of the MyD88 signaling in colorectal cancer development.
Wang L; Yu K; Zhang X; Yu S
Biomed Pharmacother; 2018 Nov; 107():177-184. PubMed ID: 30086464
[TBL] [Abstract][Full Text] [Related]
2. MyD88: At the heart of inflammatory signaling and cardiovascular disease.
Bayer AL; Alcaide P
J Mol Cell Cardiol; 2021 Dec; 161():75-85. PubMed ID: 34371036
[TBL] [Abstract][Full Text] [Related]
3. Cell-intrinsic TLR2/MyD88 pathway in breast and colon cancer.
Kuo AH; Scheeren FA
Cell Cycle; 2014; 13(24):3785-6. PubMed ID: 25457615
[No Abstract] [Full Text] [Related]
4. Toll-mediated airway homeostasis is essential for fly survival upon injection of RasV12-GFP oncogenic cells.
Ji S; Zhou X; Hoffmann JA
Cell Rep; 2024 Feb; 43(2):113677. PubMed ID: 38236774
[TBL] [Abstract][Full Text] [Related]
5. When human cells meet bacteria: precision medicine for cancers using the microbiota.
Zhang H; Sun L
Am J Cancer Res; 2018; 8(7):1157-1175. PubMed ID: 30094091
[TBL] [Abstract][Full Text] [Related]
6. MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.
de Groen RAL; Schrader AMR; Kersten MJ; Pals ST; Vermaat JSP
Haematologica; 2019 Dec; 104(12):2337-2348. PubMed ID: 31699794
[TBL] [Abstract][Full Text] [Related]
7. MyD88 mediates colorectal cancer cell proliferation, migration and invasion via NF‑κB/AP‑1 signaling pathway.
Zhu G; Cheng Z; Huang Y; Zheng W; Yang S; Lin C; Ye J
Int J Mol Med; 2020 Jan; 45(1):131-140. PubMed ID: 31746347
[TBL] [Abstract][Full Text] [Related]
8. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.
Hunter ZR; Xu L; Tsakmaklis N; Demos MG; Kofides A; Jimenez C; Chan GG; Chen J; Liu X; Munshi M; Gustine J; Meid K; Patterson CJ; Yang G; Dubeau T; Samur MK; Castillo JJ; Anderson KC; Munshi NC; Treon SP
Blood Adv; 2018 Nov; 2(21):2937-2946. PubMed ID: 30401751
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.
Weber ANR; Cardona Gloria Y; Çınar Ö; Reinhardt HC; Pezzutto A; Wolz OO
Cancer Immunol Immunother; 2018 Nov; 67(11):1797-1807. PubMed ID: 30203262
[TBL] [Abstract][Full Text] [Related]
10. Cell-type specific MyD88 signaling is required for intestinal tumor initiation and progression to malignancy.
Holtorf A; Conrad A; Holzmann B; Janssen KP
Oncoimmunology; 2018; 7(8):e1466770. PubMed ID: 30221070
[TBL] [Abstract][Full Text] [Related]
11. Modeling MyD88 Deficiency
Craig-Mueller N; Hammad R; Elling R; Alzubi J; Timm B; Kolter J; Knelangen N; Bednarski C; Gläser B; Ammann S; Ivics Z; Fischer J; Speckmann C; Schwarz K; Lachmann N; Ehl S; Moritz T; Henneke P; Cathomen T
Front Immunol; 2020; 11():608802. PubMed ID: 33424861
[TBL] [Abstract][Full Text] [Related]
12.
Alcoceba M; García-Álvarez M; Medina A; Maldonado R; González-Calle V; Chillón MC; Sarasquete ME; González M; García-Sanz R; Jiménez C
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628381
[TBL] [Abstract][Full Text] [Related]
13. MyD88 and Its Inhibitors in Cancer: Prospects and Challenges.
Song J; Li Y; Wu K; Hu Y; Fang L
Biomolecules; 2024 May; 14(5):. PubMed ID: 38785969
[TBL] [Abstract][Full Text] [Related]
14. A novel immunogenic cell death-related gene risk signature can identify biomarkers of gliomas and predict the immunotherapeutic response.
Tang X; Wang K; Yang J; Wang Y; Yan Z
Am J Cancer Res; 2024; 14(1):324-343. PubMed ID: 38323285
[TBL] [Abstract][Full Text] [Related]
15. Traversing through the Mechanistic Event Analysis in IL-6 and IL-17 Signaling for a New Therapeutic Paradigm in NSCLC.
Khilwani R; Singh S
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279220
[TBL] [Abstract][Full Text] [Related]
16. Blocking MyD88 signaling with MyD88 inhibitor prevents colitis-associated colorectal cancer development by maintaining colonic microbiota homeostasis.
Xie B; Wang B; Shang R; Wang L; Huang X; Xie L
Sci Rep; 2023 Dec; 13(1):22552. PubMed ID: 38110638
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives.
Mukherjee S; Patra R; Behzadi P; Masotti A; Paolini A; Sarshar M
Front Immunol; 2023; 14():1244345. PubMed ID: 37822929
[TBL] [Abstract][Full Text] [Related]
18. Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases.
Von Roemeling CA; Doonan BP; Klippel K; Schultz D; Hoang-Minh L; Trivedi V; Li C; Russell RA; Kanumuri RS; Sharma A; Tun HW; Mitchell DA
Clin Cancer Res; 2023 May; 29(9):1751-1762. PubMed ID: 36749885
[TBL] [Abstract][Full Text] [Related]
19. Network-Based Elaboration of the Efficacy of the Dachangshu (BL25) and Tianshu (ST25) Points in the Treatment of Functional Constipation in Children through Inflammation, Adipocytokine, or Leptin Pathways.
Xu Y; Xu H; Wang X; Wen H; Guan H; Gao F; Xu H; Jing W; Li J; Mei Y; Li W; Chen Q; Liu F; Cui H
Evid Based Complement Alternat Med; 2022; 2022():5315927. PubMed ID: 36523422
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
